RxDoctor Payments Data

Rosalyn McFarland

Psychiatric/Mental Health · Brown Deer, WINPI 1821245028

Payments from drug & device makers

$186in general payments, 2019–2025

Across 10 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$45
  • Lilly USA, LLC$35
  • Pear Therapeutics (US), Inc.$21
  • Vanda Pharmaceuticals Inc.$19
  • Medicomp Inc$18
  • Takeda Pharmaceuticals U.S.A., Inc.$18
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$45
Lilly USA, LLC2$35
Pear Therapeutics (US), Inc.1$21
Vanda Pharmaceuticals Inc.1$19
Medicomp Inc1$18
Takeda Pharmaceuticals U.S.A., Inc.1$18
AbbVie1$17
Abbott1$14

How this compares

$186 in reported general payments places this provider in the 35th percentile of 384 psychiatric/mental health providers in Wisconsin.

See all psychiatric/mental health providers in Wisconsin

Medicare billing

Part B allowed, 2024
$5,780
Medicare patients
11
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate17$50,062
OzempicSemaglutide22$27,211
RexultiBrexpiprazole15$22,132
ConcertaMethylphenidate Hcl24$21,146
EliquisApixaban14$10,025
Aripiprazole50$5,895
Fluphenazine Hcl16$2,756
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$1,538
Hydroxyzine Hcl60$1,523
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,401
Vilazodone Hcl12$1,143
Memantine Hcl13$1,107
Divalproex Sodium ErDivalproex Sodium14$879
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine16$856
Olanzapine32$813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$35$81332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 384 psychiatric/mental health providers in Wisconsin.

Other psychiatric/mental health in Brown Deer

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →